Trade News  |  26 November 2019
Finland
Media

BASF launches Hepacor in Switzerland for the dietary management of Non-Alcoholic Fatty Liver Disease

Oslo, Norway November 26, 2019 BASF Nutrition & Health is introducing Hepacor® in Switzerland, a product produced with proprietary technology dedicated to help patients manage Non-Alcoholic Fatty Liver Disease (NAFLD). With the launch in Switzerland, BASF is bringing Hepacor to the first market in continental Europe.

Containing highly concentrated and purified eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), Hepacor is uniquely designed to correct the nutritional deficiency of patients with NAFLD and can address a buildup of fat in the liver, known as steatosis, in NAFLD patients[1],[2]. Hepacor will be marketed, sold and distributed as a food for special medical purposes across Switzerland through Ideogen, a Swiss pharmaceutical company with expertise in specialty care.

NAFLD is one of the most common forms of chronic liver disease worldwide. Studies have shown that NAFLD patients suffer from EPA and DHA deficiency. A clinical study has shown that Hepacor corrects this deficiency and raises the levels of these important fatty acids in the blood[3]. Increasing the levels of EPA and DHA can help to reduce the fat burden in the liver[4] by improving the liver’s ability to process excessive pre-existing fat and at the same time inhibit the creation of new fat from dietary carbohydrates[5].

With ~25% of people in Switzerland living with NAFLD[6], Hepacor can contribute to their liver health by raising the levels of EPA and DHA needed for managing this chronic liver disease.

“The launch of Hepacor in Switzerland marks a major milestone in BASF’s plans to commercialize a dedicated solution for NAFLD management globally. Together with Ideogen in Switzerland, the BASF team has undergone a rigorous process to bring Hepacor to continental Europe and address a growing concern for patients with NAFLD,” says Christoph Garbotz, Head of Commercial Management Advanced Health Solutions, BASF. “With our European production and supply chain set up successfully, we are ready to collaborate with interested partners in greater Europe.”

Hepacor is manufactured in Norway using a patented purification technology to reduce persistent organic pollutants and other substances like unwanted lipids such as cholesterol, which are naturally found in all fish oil-based products. Research on rodents has shown that one specific environmental pollutant, PCB 153, contributes to the development of NAFLD[7],[8]. Hepacor is manufactured to minimize unnecessary exposure of NAFLD patients to such unwanted components of fish oil.

Companies interested in distribution opportunities for Hepacor outside Switzerland should contact the Advanced Health Solutions, BASF, commercial team: Christoph Garbotz at christoph.garbotz@basf.com or Abhijit Natu at abhijit.natu@basf.com.

End-consumers and health care professionals that want to learn more about Hepacor in Switzerland please contact

            Ideogen A.G.

            Customer Care: +41 43 311 52 52

 

[1] Musa-Veloso K. Systematic Review and Meta-Analysis of Controlled Intervention Studies on the Effectiveness of Long-Chain Omega-3 Fatty Acids in Patients with Nonalcoholic Fatty Liver Disease. Nutr Rev. 2018, 76 æ88æ9, 581-602.

[2] Jump DB et al. Omega-3 Polyunsaturated Fatty Acids as a Treatment Strategy for Nonalcoholic Fatty Liver Disease. Pharmacol & Therapeut 2018, 181, 108-125

[3] Tobin, D. et al. Evaluation of a High Concentrate Omega-3 for Correcting the Omega-3 Fatty Acid Nutritional Deficiency in Non-Alcoholic Fatty Liver Disease (CONDIN). Nutrients 2018, 10, 1126.

[4] Musa-Veloso K. Systematic Review and Meta-Analysis of Controlled Intervention Studies on the Effectiveness of Long-Chain Omega-3 Fatty Acids in Patients with Nonalcoholic Fatty Liver Disease. Nutr Rev. 2018, 76 æ88æ9, 581-602.

[5] Jump DB et al. Omega-3 Polyunsaturated Fatty Acids as a Treatment Strategy for Nonalcoholic Fatty Liver Disease. Pharmacol & Therapeut 2018, 181, 108-125

[6] Younossi, Z. M. et al. Global Epidemiology of Nonalcoholic Fatty Liver Disease — Meta-Analytic Assessment of Prevalence, Incidence, and Outcomes. Hepatology 64, 73–84 (2016)

[7] Shi, X. et al. Metabolomic Analysis of the Effects of Polychlorinated Biphenyls in Non-alcoholic Fatty Liver Disease. Proteome Res. 2012 July 6; 11(7): 3805–3815

[8] Wahlang, B. et al. Polychlorinated Biphenyl 153 Is a Diet-dependent Obesogen Which Worsens Nonalcoholic Fatty Liver Disease In Male C57BL6/J Mice. J Nutr Biochem. 2013 September ; 24(9): 1587–1595

 

About BASF’s Nutrition & Health division

BASF Nutrition & Health provides a comprehensive product and service portfolio for the human and animal nutrition, pharmaceutical, ethanol and flavor & fragrance industries. Together with our customers, we play an active role in enhancing the nutrition, health and wellbeing of consumers all over the world. Our products fulfill the highest safety, regulatory and sustainability standards. Our human nutrition solutions include vitamins and carotenoids, plant sterols, lutein and sterol esters, emulsifiers, high-concentrated omega-3 fatty acids, human milk oligosaccharide and peptides. Vitamins and carotenoids also form an important part of our animal nutrition portfolio, as do other feed additives such as trace elements, enzymes and organic acids. We provide the pharmaceutical industry with a broad range of excipients and selected large-volume active pharmaceutical ingredients such as ibuprofen and omega-3 fatty acids. Leveraging our advanced technology, we create high performance industrial enzymes for different markets, such as ethanol production. Furthermore, we offer aroma ingredients such as citral, geraniol and L-menthol. BASF Nutrition & Health operates sites in Europe, North America, South America and in Asia-Pacific. For more information, go to www.basf.com.

About BASF

At BASF, we create chemistry for a sustainable future. We combine economic success with environmental protection and social responsibility. The approximately 122,000 employees in the BASF Group work on contributing to the success of our customers in nearly all sectors and almost every country in the world. Our portfolio is organized into six segments: Chemicals, Materials, Industrial Solutions, Surface Technologies, Nutrition & Care and Agricultural Solutions. BASF generated sales of around €63 billion in 2018. BASF shares are traded on the stock exchange in Frankfurt (BAS) and as American Depositary Receipts (BASFY) in the U.S. Further information at www.basf.com

 

P-19-408

 

Benjamin Solms-Rusch
+49 621 60-55042
+49 1525 6401487
News Release

News Release

News releases via push notification directly to your smartphone

Last Update 26 November 2019